These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27364124)

  • 21. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.
    Li HJ; Sun QM; Liu LZ; Zhang J; Huang J; Wang CH; Ding R; Song K; Tong Z
    Oncol Rep; 2015 Aug; 34(2):795-802. PubMed ID: 26082242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma.
    Peng W; Feng J
    Biomed Pharmacother; 2016 Feb; 77():65-71. PubMed ID: 26796267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble CXCL16 promotes TNF-α-induced apoptosis in DLBCL via the AMAD10-NF-κB regulatory feedback loop.
    Yang H; Qiu B; Chen S; Xun Y; Pan Y; Chen M; Li WX; Liao W; El-Ashram S; Yang A; Liu F
    Cell Biol Int; 2019 Aug; 43(8):863-874. PubMed ID: 31033093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.
    He S; Miao X; Wu Y; Zhu X; Miao X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Wang Y; Xu X
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):561-72. PubMed ID: 26498772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
    Yang X; Fang D; Li M; Chen J; Cheng Y; Luo J
    Med Sci Monit; 2021 Mar; 27():e929431. PubMed ID: 33764958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
    Peng W; Wu J; Feng J
    Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
    Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
    Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stress-Induced Premature Senescence Promotes Proliferation by Activating the
    Wang J; Wang Z; Wang H; Wanyan Z; Pan Y; Zhu F; Tao Q; Zhai Z
    Turk J Haematol; 2019 Nov; 36(4):247-254. PubMed ID: 31327185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes mellitus potentiates diffuse large B‑cell lymphoma via high levels of CCL5.
    Zhang J; Luo J; Liu F; Wu D; Zhong Q; Zeng L; Wu Z; Zhao T; Wu L; Hao H
    Mol Med Rep; 2014 Sep; 10(3):1231-6. PubMed ID: 24938715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
    Houldsworth J; Petlakh M; Olshen AB; Chaganti RS
    Leuk Lymphoma; 2008 Nov; 49(11):2170-80. PubMed ID: 19021061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma.
    Ge X; Lv X; Feng L; Liu X; Gao J; Chen N; Wang X
    PLoS One; 2012; 7(6):e39449. PubMed ID: 22768080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
    Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
    Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
    Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.